Navigation Links
Prospective Model Outlined Potential Time and Cost Savings of,Once-Monthly Anemia Treatment

DALLAS, Texas and NUTLEY, N.J., April 23, 2007 /PRNewswire/ -- An activity-based cost analysis demonstrated that if a renal anemia treatment administered once every four weeks replaced thrice weekly administration of epoetin alfa, hemodialysis centers may save an estimated 802 nursing hours and more than $44,000 per year per 100 patients. These data, from a multi-center prospective analysis of anemia management in hemodialysis patients, were presented today during an oral session at the American Nephrology Nurses' Association (ANNA) 38th National Symposium in Dallas, TX.

"Nephrology nurses serve a pivotal role in the care of patients with renal anemia associated with chronic kidney disease," said Sheila Doss, RN, CNN, CCRA, Nursing Director of Research, Satellite Healthcare, Inc. and one of the lead study investigators. "This analysis shows that a once-monthly anemia treatment may significantly reduce the time nurses spend managing the administration of renal anemia medication, allowing us to devote more time to other important aspects of patient care."

About the Analysis

The primary objective of this analysis was to evaluate time and associated in-center supply costs observed while administering epoetin alfa three times a week in patients with renal anemia receiving dialysis, and to model the potential time and cost savings that could be expected if patients switched to a once every four week renal anemia treatment. Researchers concluded that in- center treatment of renal anemia three times a week can be labor-intensive and expensive. The analysis showed that if 100 percent of the patients were given a renal anemia treatment that could be dosed once every four weeks, a greater than 10-fold reduction in time and a similar drop in corresponding costs associated with renal anemia management could result. The researchers noted that time savings are the major contributor to total cost savings.
'"/>




Page: 1 2 3

Related medicine technology :

1. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
4. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
5. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
6. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
7. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
8. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
9. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
10. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
11. St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

Post Your Comments:
(Date:12/2/2009).... 2 Novartis announced today that ...n Tasigna® (nilotinib) 200 mg capsules in a f...trength of the company,s hematology portfolio in a..., at the 51st American Society of Hematology (ASH)...any,s current therapies and investigational agents...
(Date:12/1/2009)...ire/ -- Reportlinker.com announces that a new mark...,, Medical Oxygen Systems - Global Market Opp...164334/Medical-Oxygen-Systems---Global-Market-Oppo...tems market for home healthcare setting is reckone...th expectations stem from demographic factors such...
(Date:12/1/2009)...ire/ -- Reportlinker.com announces that a new mark...,, Molecular Diagnostics - A World Market Revi...lecular-Diagnostics---A-World-Market-Review.html ... by several growth factors that include the need f...combine optimized sample preparation, analysis, an...
Breaking Medicine Technology:Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 2Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 3Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 4Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 5Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 6Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 7Reportlinker Adds Molecular Diagnostics - A World Market Review 2Reportlinker Adds Molecular Diagnostics - A World Market Review 3Reportlinker Adds Molecular Diagnostics - A World Market Review 4Reportlinker Adds Molecular Diagnostics - A World Market Review 5Reportlinker Adds Molecular Diagnostics - A World Market Review 6LifeNet Health Announces First Bio Implant with New Preservation Technology 6088 1LifeNet Health Announces First Bio Implant with New Preservation Technology 6088 2RBC Life Sciences Ranked as One of the Top 100 Workplaces in the Dallas Fort Worth Area 6084 1RBC Life Sciences Ranked as One of the Top 100 Workplaces in the Dallas Fort Worth Area 6084 2Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 1Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 2Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 3Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 4Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 5Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 6Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 7
... EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jun 6, 200...nnounced today that two,abstracts exploring Phase ...fe in treatment-failure gout patients will be,pres...ULAR) 2007,Annual Congress taking place June 13 - ...recombinant porcine urate oxidase currently,in Pha...
... SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio ...development of DNA vaccines,for cancers and infect...o treat localized cancers, announced today that th... positive interim,safety and tolerability data on ... using Inovio,s electroporation technology for,int...
Other Medicine Technology:Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress 2Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress 3Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress 4Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 2Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 3Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 4Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 5
(Date:12/2/2009)...Leading medical device software engineering consul...13485 certification. A relatively few medical devi...ally achieved ISO 13485 certification. Many medica...dhere to other ISO standards as well. However, it ...ineering consulting firm to achieve the rigorous q...
(Date:12/2/2009)...2 Targeted breast ultra... lumps, is a safe, reliable and cost-effective alt...40, according to the findings of two studies prese...al Society of North America (RSNA). ,, "By perf...ce the number of expensive and avoidable invasive ...
(Date:12/2/2009)...rge-scale clinical trial presented today at the an...America (RSNA) provide the first strong evidence o...omen with dense breasts who are at elevated risk f... that MRI is highly sensitive in depicting early b...with ultrasound in addition to mammography signifi...
(Date:12/1/2009)..., Dec. 1 Reportlinker.com announce...n its catalogue: ,, Emerging Clinical Trial L... healthcare and regulatory environment ,, ht...al-Trial-Locations---India-Market-dynamics-and-the...ml ,, Over the last decade pharmaceutical and ...
(Date:12/1/2009)..., Dec. 1 A scientist wh... pain -- and ways we can control and relieve it --...yer Award for Psychology. ,, Ronald Melzack, ps...n Montreal, was selected for the award from among ...point of injury but instead in their brain through...
Breaking Medicine News(10 mins):Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 2Health News:Annual screening with breast ultrasound or MRI could benefit some women 2Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Health News:Scientist Who Helps Explain Pain Wins Grawemeyer Award 2
...ally take anti-inflammatory drugs to treat osteoar... side effects. Of late, people are switching over ... A recent study investigated the efficacy of a...n the November2006 issue of Arthritis & Rheumatism...
...n the Netherlands capital have increased security ...with broken bones under mysterious circumstances//...bies were found last week at the city's Free Unive...who had been in hospital since birth was found wit...
...ilize a debt ridden NHS hospital's radiotherapy de...criticism from the union and the conservatives//. ...ch hospital in Suffolk, suggestions came in from t...rding to the calculations made by the managers, th...
...ong the known value adds of vegetables, this one r... and aging has shown that eating vegetables is a s...which may even retrograde any signs of dementia re... servings of vegetables were nearly five years you...
...ment of pride of people of the Ottawa region when ...Mental Health Centre which offers// psychiatric c...on, 400,000-square-foot facility puts 188 inpatien... $132 million, 400,000-square-foot hospital can ac...
...alf of Chinese middle-aged men show symptoms of de...weating as well as a fading interest// in sex beca... The online survey released Thursday found that 52...ine. The survey was conducted by the Beijing ...
Other Medicine News:Health News:Acupuncture for chronic pain in Osteoarthritis patients 2Health News:Pet Peeves: Conservatives Howl at Proposal to Share NHS Hosp by Pets and People 2
Tying Forceps - Curved
Nordan Straight Tying Forceps
McPherson Angled Tying Forceps
Clayman - McPherson Angled Tying Forceps
Medicine Products: